Autoimmunity in atherosclerosis: Lessons from experimental models

Lupus

Volumn 9, Issue 3, 2000, Pages 223-227

  George, J ^a   Afek, A ^a   Gilburd, B ^a   Harats, D ^a   Shoenfeld, Yehuda ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Antiphospholipid antibodies; Atherosclerosis; Autoimmunity; HSP 60 65; OxLDL; 2 glycoprotein I

Indexed keywords

AUTOANTIGEN; BETA2 GLYCOPROTEIN 1; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 65;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOIMMUNITY; EXPERIMENTAL MODEL; PRIORITY JOURNAL; REVIEW;

EID: 0034090507     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120300678828190     Document Type: Review

References (39)

1. Ross R. Atherosclerosis-an inflammatory condition. N Eng J Med 1999; 340: 115-126.
2. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: Current knowledge and unanswered questions. Lab Invest 1991; 64: 5-11.
3. Wick G, Schett G, Amberger A et al. Is atherosclerosis an immunologically mediated disease? Immunol Today 1995; 16: 27-33.
4. George J, Harats D, Gilburd B, Shoenfeld Y. Emerging cross-regulatory roles of immunity and autoimmunity in atherosclerosis. Immunol Res 1996; 155: 315-322.
5. Plump AS, Smith JD, Hayek T et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein-E deficient mice created by homologous recombination in ES cells. Cell 1992; 71: 343-353.
6. Ishibashi S, Brown MS, Goldstein JL et al. Hypercholesterolemia in LDL receptor knockout mice and its reversal by adenovirus mediated gene delivery. J Clin Invest 1993; 92: 883-893.
7. Roselaar SE, Kakkanathu PX, Daugherty A. Lymphocyte populatons in atherosclerotic lesions of apo-E -/ -and LDL recepto - / -mice; Decresing density with disease progression. Arterioscler Thromb Vase Biol 1996; 16: 1013-1018.
8. Cook PJ, Lip GYH. Infectious agents and atherosclerotic vascular disease. QJM 1996; 89: 727-735.
9. Libby P, Egan D, Scarlatos S. Roles of infectious agents in atherosclerosis and restenosis. An assessment of the evidence and need for future research. Circulation 1997; 96: 4095-4103.
10. Ridker PM. Inflammation, infection and cardiovascular risk: how good is the clinical evidence. Circulation 1998; 98: 1671-1974.
11. Matsuura E, Igarashi Y, Fujimoto M et al. Heterogeneity of anticardioloipin antibodies defined by the anticardiolipin cofactor. J Immunol 1992; 148: 3885-3891.
12. Shoenfeld Y, Gharavi A, Koike T. β2GPI in the antiphospholipid (Hughes) syndrome; from a cofactor to an autoantigen-from induction to prevention of antiphospholipid syndrome. Lupus 1998; 7: 503-506.
13. Hughes GRV. The antiphospholipid syndrome: ten years on. Lancet 1993; 342: 341.
14. George J, Shoeneld Y. The antiphospholipid (Hughes) syndrome: a crossroads of autoimmunity and atherosclerosis. Lupus 1997; 6: 559-560.
15. Simantov R, LaSala JM, Lo SK et al. Activation of cultured endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96: 2211-2219.
16. George J, Blank M, Levy Y et al. Differential effects of anti-β2GPI antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation 1998; 97: 900-906.
17. Geore J, Blank M, Gilburd B et al. Immunologic characterization an dfunctional properties of murine antibodies raised against deleted mutants of β2-glycoprotein I. Int Immunol 1997; 9: 913.
18. George J, Afek A, Gilburd B et al. Induction of early atherosclerosis in LDL receptor deficient mice immunized with beta 2 glycoprotein I. Circulation 1998; 15: 1108-1115.
19. Afek A, George J, Shoenfeld Y et al. Enhanced atherosclerosis in ApoE deficient mice by immunization with β2-glycoprotein I. Pathobiology 1999; 67: 19-25.
20. George J, Harats D, Gilburd et al, Immunolocalization of β2-glycoprotein I (apolipoprotein H) to human atherosclerosis plaques: potential implications for lesion progression. Circulation 1999; 99: 2227-2230.
21. George J, Afek A. Gilburd B et al. Atherosclerosis in LDL receptor knockout mice is accelerated by immunization with anticardiolipin antibodies. Lupus 1997; 6: 723-729.
22. George J, Harats D, Gilburd B et al. Atherosclerosis related markers in systemic lupus 8: 220-226.
23. George J, Ahmed A, Adler Y et al. The prediction of coronary atherosclerosis employing artificial neural networks. Qutr J Med (In press).
24. Witztum J, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88: 1785-1792.
25. Salonen JT, Yla-Herttuala S, Yamamoto R. Antibodies against oxidized LDL and the progression of carotid atherosclerosis. Lancet 1992; 339: 883-887.
26. Bergmark C, Wu R, De Faire U et al. Patients with early onset peripheral vascular disease have increased levels of antibodies against oxidized LDL. Arterioscler Thromb Vase Biol 1995; 15: 441-445.
27. Puurunen M, Manttari M, Mannine Vesa et al. Antibodies against oxidized low density lipoprotein predicting myocardial infarction. Arch Intern Med 1994; 154: 2605-2609.
28. George J, Harats D, Bakshi E et al. Anti-oxidized-low density lipoprotein antibody determination as a predictor of restenosis following percutaneous transluminal coronary angioplasty. Immunol Lett 1999; 68: 263-266.
29. Stemme S, Faber B, Holm J. T lymphocytes from himan atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA 1995; 92: 3893-3897.
30. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) deficient rabbits with homologeous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 1995; 92: 821-825.
31. George J, Afek A, Gilburd B et al. Hyperimmunization of apoE deficient mice with homologous MDA-low density lipoprotein suppresses early atherogenesis. Atherosclerosis 1998; 138: 147-152.
32. Freigang S, Horkko S, Miller E et al. Immunization of LDL receptor deficient mice with homologous malondialdehyde modified and native LDL reduces atherosclerosis progression by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vase Biol 1998: 18: 1972-1982.
33. George J, Blank M, Hojnik M et al. Oxidized low density lipoprotein (oxLDL) but not LDL aggravates the manifestations of antiphospholipid syndrome (APS). Clin Exp Immunol 1997; 108: 227-233.
34. Horkko S, Miller E, Dudl E et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. J Clin Invest 1996; 98: 815-825.
35. George J, Gilburd B, Langevitz P et al. β2-glycoprotein I containing immune complexes: association with thrombocytopenia and lipoprotein (a) levels. Lupus 1999; 8: 116-120.
36. Ellis J. Proteins as molecular chaprones. Cell 1987; 328: 378
37. Xu Q, Willeit J, Marosi M et al. Asociation of serum antibodies to heat shock protein 65 with carotid atherosclerosis. Lance 1993; 341: 255-259.
38. Xu Q, Dietrich H, Steiner HJ et al. Induction of arteriosclerosis in normocholesterolemic mice rabbits by immunization with heat shock protein 65. Arterioscler Thromb 1992; 12: 789-799.
39. George J, Shoenfeld Y, Afek A et al. Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein 65. Arterioscler Thromb Vase Biol 1999; 19: 505-510.